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Diagnostic Workup and Initial Treatment
The patient in this case presented in October 2000 with vague abdominal pain and under went colonoscopy-following the classical presentation in which symptoms mimic those of other diseases. Colonoscopy showed an extrinsic pressure on the cecum from a large right pelvic mass, which was con-firmed by CT scan. CA-125 at this time was slightly elevated at 145 U/mL. Exploratory laparotomy revealed a right ovarian mass, 19 cm in maximum dimension. The initial surgical procedure in November included bilateral salpingo-oophorectomy, omentectomy, appendectomy, lymph node sampling, and peritoneal biopsies. The patient had had a hysterectomy in 1987 following recurrent abnormal bleeding. Surgical pathology indicated a serous papillary cystadenocarcinoma confined to the ovary, serous tumors being the most common type. Small foci of cystadenocarcinoma were found in biopsies of the bladder and pelvic peritoneum, and malignant cells were found in washings of the right diaphragm, the colon, and the pelvis. Recovery from surgery was without unusual event. Initial staging was IIC (T2C N0 M0). With the high risk of recurrence, chemotherapy was recommended, and the patient underwent 6 cycles of paclitaxel and carboplatin without unusual side effects or toxicity. Her CA-125 returned to normal after the first cycle of chemotherapy. After her chemotherapy was concluded, she was asymptomatic. She was followed by medical and gynecologic examinations, with monitoring of CA-125 every 3 months.
Her family history does not indicate other cases of ovarian, breast, or colon cancers that are associated with hereditary ovarian cancer, although the health of her parents and second-degree relatives was not discussed. She has had a long-term problem with overweight. She does not drink alcohol, takes caffeine in limited amounts, and smokes tobacco occasionally. No medications were taken; her mild hypertension was treated with diet and weight reduction. She has never been pregnant and is not married. Previous use of birth control pills was not discussed.
Current Findings and Discussion
After a disease-free interval of 14 months, the patient's CA-125 was found to be slightly elevated (91 U/mL) upon further testing. A CT scan of the abdomen and pelvis was negative except for an enlarged external iliac lymph node (its size was not indicated). Her physical exam at this time was unremarkable, and no symptoms referable to her disease were found. No adenopathy was detected in the cervical, supraclavicular, axillary, or inguinal areas. No long-term toxicities from her previous chemotherapy were evident: no gastrointestinal symptoms or neuropathy were reported and no reports of renal problems were noted. Other laboratory tests were within normal limits.
The current standard of care for ovarian cancer is a combination of surgery, to debulk the disease, and chemotherapy, most typically a combination of a platinum-based therapy and a taxane. Carboplatin is easier to administer, has fewer side effects, and has a good level of activity in ovarian cancer and is thus chosen more frequently than cisplatin. Intraperitoneal chemotherapy for localized disease has been attempted but was not used in this case. Radiotherapy is usually included only for palliation of metastatic disease.
At this time, the question is how the patient's abnormal findings in her CA-125 and CT scan should be evaluated. Three options, not mutually exclusive, present themselves. Continued observation of the slightly elevated CA-125 is a possible first step. With continued elevation, biopsy of the enlarged lymph node becomes necessary, and with it consideration of further treatment in the case of positive findings. Recurrence appears likely, as some two thirds of ovarian cancer patients experience a recurrence in the first 2 years after primary therapy.
If the patient has a recurrence, what are the treatment options that could be presented? The most common therapy used in recurrent ovarian cancer at this time is chemotherapy, although a patient with an isolated recurrence might be a candidate for surgery. The patient's relatively long disease-free interval increases the chance that she will respond to salvage chemotherapy. 4 Cancers that recur in less than 6 months after initial chemotherapy are much less responsive to further chemotherapy. In particular, it may be possible to reintroduce the same chemotherapy regimen that was used initially, since patients who are free of disease for at least 6 months are considered to have platinum-sensitive disease and have been demonstrated to respond to platinum therapies. 5 Patients who have residual toxicities from previous platinumbased therapies would not be candidates for further platinum-based therapy; however, this does not appear to be a problem for this patient.
Should other chemotherapy agents need to be considered, the agents most commonly used in this situation are topotecan, liposomal doxorubicin, and gemcitabine. Response rates to these agents are in the area of 20% to 35%. 5 There is currently no evidence of superiority of any one of these possible agents for recurrent ovarian cancer, although platinum-sensitive patients may respond differently from nonsensitive patients. 5 A randomized phase III trial of topotecan versus liposomal doxorubicin in 474 patients who recurred after or did not respond to platinum-based therapy was reported in 2001. 6 In this trial, no overall advantage in median or progression-free survival was reported for either drug. A planned subgroup analysis found that doxorubicin did have a significant overall survival advantage among patients with platinumsensitive disease (25 months vs 17 months), so it is possible that liposomal doxorubicin would be a better choice for this platinum-sensitive patient. Survival of platinum-resistant patients in this study was better with topotecan. The 2 agents have different toxicity profiles: topotecan was associated with National Cancer Institute Common Toxicity Criteria grade 3-4 neutropenia (77% of patients) and grade 3-4 anemia (28% of patients). Liposomal doxorubicin was associated with palmar-plantar erythrodysesthesia (49% of patients), a condition characterized by reddening and inflammation of the palms and of the soles of the feet. A 40% incidence of mouth sores was also seen with this drug. In either case, therefore, the patient would be facing substantial toxicities and a rigorous course of chemotherapy treatment.
